#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3626	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2633	406.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1725	1725	C	519	C	467	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4158	438.2	0	.	n	.	0	T695C	SNP	695	695	T	1286	1286	C	469	C,G,T	419,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4158	438.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1928	1928	A	506	A,G,C	458,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4158	438.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2562	2562	C	559	C,A,T	513,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4158	438.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3188	3188	T	554	T,C,G	496,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6090	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4158	438.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2636	2636	A	576	A	506	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	836	folP	852	852	100.0	folP.l6.c4.ctg.1	2040	122.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1319	1321	AGC	200;201;202	A;G;C	178;184;180	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1692	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3843	131.9	1	SNP	p	S91F	0	.	.	271	273	TCC	858	860	TCC	155;155;156	T;C;C	144;143;144	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1692	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3843	131.9	1	SNP	p	D95N	0	.	.	283	285	GAC	870	872	GAC	153;153;153	G;A;C	138;141;138	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1692	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3843	131.9	1	SNP	p	D95G	0	.	.	283	285	GAC	870	872	GAC	153;153;153	G;A;C	138;141;138	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	756	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1848	122.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	508	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1575	96.2	0	.	n	.	0	C187G	SNP	187	187	C	840	840	G	183	G	168	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1698	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3284	154.5	1	SNP	p	D86N	0	.	.	256	258	GAC	723	725	GAC	189;190;190	G;A,C;C	166;158,1;167	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1698	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3284	154.5	1	SNP	p	S87I	0	.	.	259	261	AGT	726	728	AGT	192;192;192	A;G;T	161;171;166	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1698	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3284	154.5	1	SNP	p	S87R	0	.	.	259	261	AGT	726	728	AGT	192;192;192	A;G;T	161;171;166	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1698	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3284	154.5	1	SNP	p	S87W	0	.	.	259	261	AGT	726	728	AGT	192;192;192	A;G;T	161;171;166	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1698	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3284	154.5	1	SNP	p	S88P	0	.	.	262	264	TCC	729	731	TCC	192;192;192	T,C;C;C	171,1;170;169	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1580	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3363	140.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1927	1929	GGC	185;186;184	G;G;C	168;169;163	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1430	1432	GCA	154;155;155	G,A;C;A	140,1;138;144	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1433	1435	ATC	156;156;158	A;T,C;C	147;141,1;147	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1445	1447	GTG	155;157;155	G;T;G,A,T,C	140;143;138,1,1,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1445	1447	GTG	155;157;155	G;T;G,A,T,C	140;143;138,1,1,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1949	1951	ACC	120;120;119	A,C;C,A;C	105,1;107,1;110	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2003	2005	GCG	123;123;123	G;C,G,A;G,T	108;97,1,1;102,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2003	2005	GCG	123;123;123	G;C,G,A;G,T	108;97,1,1;102,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2126	2128	GGC	113;114;115	G,C;G;C	101,1;101;104	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2135	2137	GGC	118;118;118	G;G,C;C,A	109;108,1;108,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1064	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2800	113.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2153	2155	CCG	116;116;115	C,G;C,T;G	99,1;105,1;100	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1356	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3762	108.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1888	1890	CTG	130;130;130	C;T;G,C	108;104;108,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	846	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2364	106.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	879	879	C	136	C	132	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	104	porB1a	984	277	91.1	porB1a.l15.c4.ctg.1	1476	20.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1224	1226	AAT	8;8;8	A;A;T	7;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	104	porB1a	984	277	91.1	porB1a.l15.c4.ctg.1	1476	20.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1227	1229	AAT	8;8;7	A;A;T	8;8;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	104	porB1a	984	277	91.1	porB1a.l15.c4.ctg.1	1476	20.8	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1239	1241	GTT	7;7;7	G;T;T	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	104	porB1a	984	277	91.1	porB1a.l15.c4.ctg.1	1476	20.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1251	1253	GCA	7;7;7	G;C;A	5;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	104	porB1a	984	277	91.1	porB1a.l15.c4.ctg.1	1476	20.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1274	1276	GTA	7;7;7	G;T;A	7;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	104	porB1a	984	277	91.1	porB1a.l15.c4.ctg.1	1476	20.8	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1283	1283	A	7	A	6	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	G38E	NONSYN	112	114	GGA	477	479	GAA	177;176;174	G;A;A	152;151;154	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	S46G	NONSYN	136	138	AGC	501	503	GGC	170;169;168	G;G;C	149;153;145	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	507	509	GGA	167;168;168	G;G;A	147;152;149	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	624	626	GCT	161;161;159	G;C;T	143;140;147	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	630	632	AGC	162;162;163	A;G;C	147;144;150	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	722	723	CG	166;166	C,A;G	152,1;154	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	725	727	CAG	164;166;164	C;A,T,G;G	152;150,1,1;151	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	729	731	AAA	162;161;161	A;A;A	149;150;148	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	792	794	GAA	151;149;148	G;A;A	141;140;140	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	816	818	GCA	148;147;147	G;C;A	140;135;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	924	926	CGA	145;146;147	C;G;A	128;130;128	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1008	1010	ACT	137;136;138	A;C;T,G	122;126;121,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1011	1013	CAT	138;138;138	C;A;T	125;130;125	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1017	1019	ATG	138;138;136	A;T;G	130;130;122	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	.	MULTIPLE	766	767	AC	1131	1133	GCA	140;140;140	G;C;A	131;128;129	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1135	1137	CGG	140;139;139	C;G;G	126;129;129	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1138	1138	A	141	A	128	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	1	SNP	p	G120K	1	.	.	358	360	AAG	722	724	CGG	166;166;166	C,A;G;G	152,1;154;147	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	1	SNP	p	D121N	0	.	.	361	363	GAC	725	728	CGC	164;164;162	C;G;C	152;151;151	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	790	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1754	131.1	1	SNP	p	A121D	1	.	.	361	363	GAC	725	728	CGC	164;164;162	C;G;C	152;151;151	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2042	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5332	114.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2217	2219	AAT	119;120;120	A;A;T	109;108;109	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	190	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1530	37.2	1	SNP	p	V57M	1	.	.	169	171	ATG	762	764	ATG	72;72;72	A;T;G	64;66;64	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
